Cipla introduces generic Xeloda
Cipla has secured rights from MSN Laboratories to market and distribute capecitabine 150-mg and 500-mg tablets.
The product is the generic version of Genentech’s Xeloda.
Capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with Dukes C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred, and also indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
The product had a market value of approximately $178 million for the 12-month period ending June 2018, according to IQVIA data.
The product is the generic version of Genentech’s Xeloda.
Capecitabine tablets are indicated as a single agent for adjuvant treatment in patients with Dukes C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred, and also indicated for the treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing chemotherapy.
The product had a market value of approximately $178 million for the 12-month period ending June 2018, according to IQVIA data.